Barinthus Biotherapeutics plc
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William James Enright
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Zeus Building Didcot OX United Kingdom OX11 0DF
- IPO Date
- Apr 30, 2021
- CIK
- 0001828185
- Website
- barinthusbio.com
- Similar Companies
- Business
- Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage biopharmaceutical company focused on developing antigen-specific immunotherapies that guide T cells to treat immunology and inflammatory diseases, infectious diseases, and oncology indications. The company offers a pipeline of novel T-cell immunotherapeutics including VTP-1000, a SNAP-Tolerance Immunotherapy (SNAP-TI) platform candidate in Phase 1 trials for celiac disease to restore immune non-responsiveness to gluten; VTP-300 for chronic hepatitis B; VTP-200 for high-risk human papillomavirus; VTP-850 for prostate cancer; and viral platform programs such as VTP-600 targeting MAGE-A3 and NY-ESO1 antigens, VTP-500 for Middle East respiratory syndrome, VTP-400 for shingles, and Vaxzevria for COVID-19 prevention. Founded in 2016 as an Oxford University spin-out and formerly known as Vaccitech plc until its rebranding in November 2023, Barinthus Biotherapeutics plc maintains headquarters in Altrincham, Cheshire, United Kingdom, with additional operations in the United States including Germantown, Maryland. In September 2025, the company entered a definitive all-stock merger agreement with Clywedog Therapeutics, Inc., anticipated to close in the first half of 2026, to create a combined entity advancing clinical-stage candidates in metabolic and autoimmune diseases such as Type 1 diabetes, Type 2 diabetes, and celiac disease, with four clinical data readouts expected within 18 months post-closing; this follows a 2025 strategic refocus on immunology and inflammatory diseases emphasizing VTP-1000 and the SNAP-TI platform.
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?
Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?
Short Interest in Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Grows By 72.8%
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?
Contrasting Barinthus Biotherapeutics (NASDAQ:BRNS) & Oncobiologics (NASDAQ:OTLK)
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Barinthus Biotherapeutics plc (NASDAQ: BRNS)
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS
BRNS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Barinthus Biotherapeutics plc Is Fair to Shareholders
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion